Natera, Inc. (NASDAQ:NTRA) Receives $125.69 Consensus Target Price from Brokerages

Natera, Inc. (NASDAQ:NTRA) has been given an average recommendation of “Buy” by the sixteen brokerages that are presently covering the company, Marketbeat Ratings reports. Sixteen investment analysts have rated the stock with a buy recommendation. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $125.69.

A number of equities analysts have weighed in on NTRA shares. Piper Sandler reaffirmed an “overweight” rating and set a $150.00 target price on shares of Natera in a research note on Friday, September 13th. StockNews.com raised Natera from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Leerink Partners raised their price target on Natera from $140.00 to $150.00 and gave the company an “outperform” rating in a report on Thursday, October 17th. Sanford C. Bernstein upped their price target on shares of Natera from $125.00 to $135.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. Finally, Stephens restated an “overweight” rating and set a $125.00 price objective on shares of Natera in a research note on Friday, August 9th.

Natera Stock Down 0.1 %

Shares of Natera stock opened at $133.97 on Friday. Natera has a 1 year low of $46.96 and a 1 year high of $140.00. The firm has a market cap of $16.57 billion, a price-to-earnings ratio of -54.68 and a beta of 1.53. The company has a 50-day moving average of $124.66 and a 200 day moving average of $114.21. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.14 and a quick ratio of 4.01.

Insider Activity at Natera

In other news, insider Jonathan Sheena sold 12,000 shares of the stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $121.01, for a total value of $1,452,120.00. Following the transaction, the insider now owns 287,441 shares in the company, valued at $34,783,235.41. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, insider Jonathan Sheena sold 12,000 shares of the business’s stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $121.01, for a total transaction of $1,452,120.00. Following the completion of the sale, the insider now owns 287,441 shares of the company’s stock, valued at $34,783,235.41. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Steven Leonard Chapman sold 4,523 shares of the firm’s stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $130.40, for a total value of $589,799.20. Following the completion of the transaction, the chief executive officer now directly owns 191,163 shares in the company, valued at approximately $24,927,655.20. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 47,464 shares of company stock worth $5,849,977. 7.60% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Itau Unibanco Holding S.A. purchased a new position in shares of Natera during the 2nd quarter valued at $28,000. Quarry LP lifted its position in shares of Natera by 148.4% in the second quarter. Quarry LP now owns 318 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 190 shares in the last quarter. GAMMA Investing LLC boosted its stake in shares of Natera by 50.0% in the second quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock worth $35,000 after acquiring an additional 108 shares during the period. Covestor Ltd boosted its stake in shares of Natera by 34.3% in the third quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock worth $47,000 after acquiring an additional 95 shares during the period. Finally, Tobam purchased a new stake in shares of Natera during the second quarter worth about $74,000. 99.90% of the stock is owned by hedge funds and other institutional investors.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.